Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
13 Results for "
HLM
" in MedChemExpress (MCE) Product Catalog:
Products (13)
13 Results for "HLM" in MCE Product Catalog:
10
10 Cited Publications
Cat. No.: HY-16667
CAS No.: 353519-63-8
Target:
Research Areas:
HLM006474 is a pan E2F inhibitor, which inhibits E2F4 DNA-binding with an IC50 of 29.8 μM in A375 cells.
Cat. No.: HY-17614
CAS No.: 945531-77-1
Synonyms: SMT C1100; BMN 195; VOX-C1100
Target:
Research Areas:
Ezutromid (SMT C1100) is a first-in-class, orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM. Ezutromid can be used for the research Duchenne muscular dystrophy (DMD). Ezutromid inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM .
Category:
Cardiovascular Disease Alkaloids Other Alkaloids Aconitum carmichaeli Debx. Plants Disease Research Fields Ranunculaceae Extract
Target:
Cat. No.: HY-RS09836
Target:
Research Areas:
OSBP2 Human Pre-designed siRNA Set A contains three designed siRNAs for OSBP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-114663
CAS No.: 1883284-94-3
Target:
Research Areas:
FDU-PB-22 is a new synthetic cannabinoid that is rapidly metabolized in HLM, with a half-life of 12.4 minutes .
Cat. No.: HY-176715
CAS No.: 2981435-59-8
Target:
Research Areas:
Kv7.2 activator-1 (Compound 8) is a Kv7.2/3 activator with an EC50 of 178 nM. Kv7.2 activator-1 has a long half-life of 120 minutes in HLM .
Cat. No.: HY-146111
CAS No.: 2667681-57-2
IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg .
Cat. No.: HY-153970
CAS No.: 1632002-28-8
Target:
Research Areas:
URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC50 of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC50 of 4.2 μM. URAT1 inhibitor 7 can be used for gout research .
Cat. No.: HY-125505
CAS No.: 1622159-00-5
Target:
Research Areas:
BI-11634 is an orally active factor Xa inhibitor and a CYP3A4 substrate. The apparent Km values for BI-11634 metabolism are 23 μM in human liver microsomes (HLMs) and 7.6 μM with recombinant CYP3A4. BI-11634 can be used for thromboembolic disease and CYP3A4-mediated drug metabolism research .
Cat. No.: HY-17614R
CAS No.: 945531-77-1
Synonyms: SMT C1100 (Standard); BMN 195 (Standard); VOX-C1100 (Standard)
Target:
Research Areas:
Ezutromid (Standard) is the analytical standard of Ezutromid. This product is intended for research and analytical applications. Ezutromid (SMT C1100) is a first-in-class, orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM. Ezutromid can be used for the research Duchenne muscular dystrophy (DMD). Ezutromid inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM .
Cat. No.: HY-155141
CAS No.: 3003751-14-9
Target:
Research Areas:
hCYP3A4-IN-1 (compound C6) is a potent, orally active hCYP3A4 inhibitor. hCYP3A4-IN-1 shows the IC50 values of 43.93 nM and 153.00 nM against hCYP3A4 in human liver microsomes (HLMs) and CHO-3A4 stably transfected cell line, respectively. hCYP3A4-IN-1 potently inhibits CYP3A4-catalyzed N-ethyl-1,8-naphthalimide (NEN) hydroxylation in a competitive manner (Ki = 30.00 nM) .
Cat. No.: HY-125505A
CAS No.: 864295-20-5
Research Areas:
BI-11634 free base is an orally active factor Xa inhibitor and a CYP3A4 substrate. The apparent Km values for BI-11634 free base metabolism are 23 μM in human liver microsomes (HLMs) and 7.6 μM with recombinant CYP3A4. BI-11634 free base can be used for thromboembolic disease and CYP3A4-mediated drug metabolism research .
Cat. No.: HY-135541
CAS No.: 365462-24-4
Synonyms: YM150 maleate
Target:
Research Areas:
Darexaban maleate (YM150 maleate) is a direct factor Xa inhibitor with activity in preventing venous thromboembolism. The major metabolite of Darexaban maleate in humans is Darexaban glucitol, which acts pharmacologically. The glucitolation reaction of Darexaban maleate is mainly catalyzed by UGT1A9 and UGT1A10 in the human liver and intestine. The K(m) value of Darexaban maleate glucitolation in the liver is greater than 250 μM, while in the intestine it exhibits substrate inhibition kinetics with a K(m) value of 27.3 μM. The unbound K(m) value of Darexaban maleate is significantly reduced by the influence of fatty acid-free bovine serum albumin in both HLM and UGT1A9 .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
